These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 22998609)

  • 21. Better mycophenolic acid 12-hour trough level after enteric-coated mycophenolate sodium in patients with gastrointestinal intolerance to mycophenolate mofetil.
    Sánchez Fructuoso A; Calvo N; Moreno MA; Giorgi M; Conesa J; Barrientos A
    Transplant Proc; 2007 Sep; 39(7):2194-6. PubMed ID: 17889135
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Improvement in gastrointestinal and health-related quality of life outcomes after conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium in liver transplant recipients.
    Sterneck M; Settmacher U; Ganten T; Sarrazin C; Speidel N; Broering D; Heyne N; Paulus E; Mertens M; Fischer L
    Transplant Proc; 2014; 46(1):234-40. PubMed ID: 24507058
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Enteric-coated mycophenolate sodium reduces gastrointestinal symptoms in renal transplant patients.
    Burg M; Säemann MD; Wieser C; Kramer S; Fischer W; Lhotta K
    Transplant Proc; 2009 Dec; 41(10):4159-64. PubMed ID: 20005359
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Gastrointestinal side effects in liver transplant recipients taking enteric-coated mycophenolate sodium vs. mycophenolate mofetil.
    Lopez-Solis R; DeVera M; Steel J; Fedorek S; Sturdevant M; Hughes C; Humar A
    Clin Transplant; 2014 Jul; 28(7):783-8. PubMed ID: 24754682
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Enteric-coated mycophenolate sodium: therapeutic equivalence to mycophenolate mofetil in de novo renal transplant patients.
    Sollinger H
    Transplant Proc; 2004 Mar; 36(2 Suppl):517S-520S. PubMed ID: 15041399
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium on maximum tolerated dose and gastrointestinal symptoms following kidney transplantation.
    Shehata M; Bhandari S; Venkat-Raman G; Moore R; D'Souza R; Riad H; Bakran A; Baker R; Needham C; Andrews C
    Transpl Int; 2009 Aug; 22(8):821-30. PubMed ID: 19386081
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Long-term administration of enteric-coated mycophenolate sodium in kidney transplant patients.
    Salvadori M;
    Transplant Proc; 2005 Mar; 37(2):909-11. PubMed ID: 15848572
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Randomized trial of mycophenolate mofetil versus enteric-coated mycophenolate sodium in primary renal transplant recipients given tacrolimus and daclizumab/thymoglobulin: one year follow-up.
    Ciancio G; Burke GW; Gaynor JJ; Roth D; Sageshima J; Kupin W; Tueros L; Hanson L; Rosen A; Ruiz P; Miller J
    Transplantation; 2008 Jul; 86(1):67-74. PubMed ID: 18622280
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical evolution in the first 3 months of patients after liver transplantation in maintenance phase converted from mycophenolate mofetil to mycophenolate sodium due to gastrointestinal complications.
    Miras M; Carballo F; Egea J; Martínez C; Alvarez-López MR; Sánchez-Bueno F; Parrilla P
    Transplant Proc; 2007 Sep; 39(7):2314-7. PubMed ID: 17889175
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Tolerance of enteric-coated mycophenolate sodium in combination with calcineurin inhibitor in kidney transplant recipients: Polish experience.
    Gozdowska J; Urbanowicz AL; Galazka Z; Chmura A; Durlik M
    Transplant Proc; 2011 Oct; 43(8):2946-9. PubMed ID: 21996197
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Switching from mycophenolate mofetil to enteric-coated mycophenolate sodium in liver transplant patients with gastrointestinal complications.
    Barrera-Pulido L; Alamo-Martínez JM; Marín-Gómez LM; Suárez-Artacho G; Bernal-Bellido C; Domínguez-Usero D; Tallón-Aguilar L; Pareja-Ciuró F; Sousa-Martín JM; García-González I; Gómez-Bravo MA
    Transplant Proc; 2009; 41(6):2192-4. PubMed ID: 19715870
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Superior efficacy of enteric-coated mycophenolate vs mycophenolate mofetil in de novo transplant recipients: pooled analysis.
    Salvadori M; Bertoni E; Budde K; Holzer H; Civati G; Lien B; Arns W
    Transplant Proc; 2010 May; 42(4):1325-8. PubMed ID: 20534293
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Mycophenolate mofetil versus enteric-coated mycophenolate sodium after simultaneous pancreas-kidney transplantation.
    Rangel EB; Melaragno CS; Sá JR; Gonzalez AM; Linhares MM; Salzedas A; Medina-Pestana JO
    Transplant Proc; 2009 Dec; 41(10):4265-9. PubMed ID: 20005381
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Enteric-coated mycophenolate sodium as a steroid-sparing agent in pemphigus treatment: a retrospective study.
    De Simone C; Caldarola G; Perino F; Venier A; Guerriero G
    Dermatol Ther; 2012; 25(2):219-22. PubMed ID: 22741942
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparison of inosine-monophosphate-dehydrogenase activity in patients with enteric-coated mycophenolate sodium or mycophenolate mofetil after renal transplantation.
    Rath T; Küpper M
    Transplant Proc; 2009; 41(6):2524-8. PubMed ID: 19715967
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy and safety of enteric-coated mycophenolate sodium (myfortic) in de novo renal transplant recipients: results of a 12-month multicenter, open-label, prospective study.
    Vogt B; Antoniadis A; Klinger M; Vitko S
    Transplant Proc; 2006 Jun; 38(5):1301-6. PubMed ID: 16797288
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Renal transplant patients with gastrointestinal intolerability to mycophenolate mofetil: conversion to enteric-coated mycophenolate sodium.
    Calvo N; Sanchez-Fructuoso AI; Conesa J; Moreno A; Barrientos A
    Transplant Proc; 2006 Oct; 38(8):2396-7. PubMed ID: 17097945
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Enteric-coated mycophenolate-sodium in heart transplantation: efficacy, safety, and pharmacokinetic compared with mycophenolate mofetil.
    Lehmkuhl H; Hummel M; Kobashigawa J; Ladenburger S; Rothenburger M; Sack F; Dengler T; Hetzer R
    Transplant Proc; 2008 May; 40(4):953-5. PubMed ID: 18555088
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Lower dosing of enteric-coated mycophenolate sodium (Myfortic) can achieve target mycophenolic acid exposure rapidly in most Chinese renal transplant patients: a pilot study.
    Yin H; Qiu K; Hu XP; Li XB; Wang W; Liu LH; Zhang XD
    Int J Clin Pract Suppl; 2014 Apr; (181):31-7. PubMed ID: 24673717
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Mycophenolate mofetil is effective in the treatment of atopic dermatitis.
    Grundmann-Kollmann M; Podda M; Ochsendorf F; Boehncke WH; Kaufmann R; Zollner TM
    Arch Dermatol; 2001 Jul; 137(7):870-3. PubMed ID: 11453805
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.